Illumina's Pullback Looks Like a Buying Opportunity for Further Gain

Illumina's Pullback Looks Like a Buying Opportunity for Further Gain


We looked at the charts and indicators at the end of May and I wrote that "ILMN is dipping slightly today and might see a retracement to around $250 or so but with no signs of significant distribution ILMN could well outperform on a relative and absolute basis over the next several months." ILMN stopped short of our $250 buy level and then rallied to new highs.



from Biotech News